Bone Biologics Corporation BBLG
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- -73.77%
- 1 year
- -82.31%
- Open
- 0.403
- Prev close
- 0.3875
- Mkt cap
- 1.29M
- Vol
- 14.46K
- Avg vol
- 380.77K
- EPS
- -1.02
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.3763
- High
- 0.403
- Forward P/E
- -0.41
- Beta
- 0.74
- Short ratio
- 0.18
- Inst. own
- 4.59%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 9, 2024
- 50-d avg
- 1.34
- 200-d avg
- 1.60
- 1y target
- 16.75
3M chart
Signals (10)
| Name | Date | Ago |
|---|---|---|
| RSI: Oversold | Oct 23, 2026 | 1 week ago |
| MACD: Buy Signal | Oct 20, 2026 | 1 week ago |
| MACD: Sell Signal | Oct 15, 2026 | 2 weeks ago |
| RSI: Oversold | Oct 9, 2026 | 3 weeks ago |
| RSI: Oversold | Oct 1, 2026 | 1 month ago |
| RSI: Oversold | Sep 24, 2026 | 1 month ago |
| MACD: Buy Signal | Aug 26, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 12, 2026 | 2 months ago |
| RSI: Oversold | Aug 12, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 11, 2026 | 2 months ago |
Key statistics
- Market cap
- 2.22M
- Enterprise value
- -188.37K
- Trailing P/E
- 0.00
- Forward P/E
- -0.41
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.17
- EPS (TTM)
- -1.46
- Beta
- 0.74
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -4.83M
- Total cash
- 2.33M
- Total debt
- 0
- Return on equity
- -119.03%
- Shares outstanding
- 2.46M
- Short % of float
- 3.49%
- 50-day average
- 1.34
- 200-day average
- 1.60
Analyst view
Consensus: none
Next earnings
Aug 9, 2024
Expected Aug 9, 2024. Consensus EPS estimate -0.65.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -0.60 | -2.37 | -1.77 | -295.00% |
| Aug 9, 2024 | Jun 1, 2024 | -1.39 | -0.67 | +0.72 | +51.80% |
| Aug 9, 2024 | Jun 1, 2024 | -1.39 | — | — | — |
| May 14, 2024 | Mar 1, 2024 | -7.60 | — | — | — |
| May 14, 2024 | Mar 1, 2024 | -7.60 | -1.31 | +6.29 | +82.76% |
| Apr 4, 2024 | Dec 1, 2023 | -5.56 | — | — | — |
About Bone Biologics Corporation
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1. The company's platform technology is used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- bonebiologics.com
News
- Bone Biologics Q3 EPS $(0.17) Beats $(0.18) Estimate
- 12 Health Care Stocks Moving In Wednesday's After-Market Session
- 12 Health Care Stocks Moving In Wednesday's After-Market Session
- 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- Short Interest in Bone Biologics Corp. (NASDAQ:BBLG) Drops By 76.4%
- Bone Biologics Expands Trial Sites
- Bone Biologics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
- 12 Health Care Stocks Moving In Wednesday's After-Market Session
- 12 Health Care Stocks Moving In Wednesday's After-Market Session
- 12 Health Care Stocks Moving In Wednesday's Intraday Session
Your note
Sign in to keep a note on BBLG — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| FRELICK JEFFREY | Chief Executive Officer | Purchase | Sep 10, 2023 | 17,204 |
| WALSH DEINA H | Chief Financial Officer | Purchase | Sep 12, 2023 | 15,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| UBS Group AG | 1.32% | 32,851 | 29.57K | Sep 29, 2024 |
| Morgan Stanley | 1.14% | 28,527 | 25.68K | Sep 29, 2024 |
| HRT Financial LP | 0.89% | 22,276 | 20.05K | Sep 29, 2024 |
| Tower Research Capital LLC (TRC) | 0.07% | 1,786 | 1.61K | Sep 29, 2024 |
| CWM, LLC | 0.02% | 444 | 399 | Sep 29, 2024 |
| MFA Wealth Advisors, LLC | 0.02% | 403 | 362 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.36% | 8,910 | 8.02K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.16% | 3,936 | 3.54K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.11% | 2,747 | 2.47K | Oct 30, 2024 |